1. Homepage
  2. Equities
  3. New Zealand
  4. New Zealand Stock Exchange
  5. EBOS Group Limited
  6. News
  7. Summary
    EBO   NZEBOE0001S6

EBOS GROUP LIMITED

(EBO)
  Report
End-of-day quote New Zealand Stock Exchange  -  2022-06-30
37.81 NZD   -3.08%
06/19EBOS : Application for quotation of securities - EBO
PU
05/30EBOS : Appendix 2A
PU
04/19EBOS : Application for quotation of securities - EBO
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

NZ's EBOS to buy LifeHealthcare for $839 mln in Southeast Asia push

12/08/2021 | 03:45pm EDT

Dec 9 (Reuters) - New Zealand healthcare products distributor EBOS Group Ltd said on Thursday it would buy Australian peer LifeHealthcare for A$1.17 billion ($839.6 million), as it looks to expand into the Southeast Asia market.

Under the deal http://nzx-prod-s7fsd7f98s.s3-website-ap-southeast-2.amazonaws.com/attachments/EBO/384370/361287.pdf, EBOS will buy LifeHealthcare's Australian and New Zealand units and 51% of its Asian unit, Transmedic, from funds advised by Pacific Equity Partners and other minority holders.

"The acquisition ... represents an important step in EBOS' medical devices strategy, providing greater exposure to this high-growth sector as well as a measured entry into Southeast Asia," EBOS Chief Executive John Cullity said in a statement.

The deal is expected to increase EBOS' earnings per share by a low-double-digit percentage in 2022 on a pro-forma basis, the New Zealand-based firm said.

LifeHealthcare, one of the largest independent distributors of third-party medical devices and in-house manufactured allograft material in Australia, New Zealand and South East Asia, was bought by Pacific Equity Partners in 2018.

EBOS said it would undertake a retail offering to raise up to A$100 million, a share placement to raise A$642 million and a loan of A$540 million to fund the deal.

The company also said its net profit after tax (NPAT) grew 14% in the four months to October and that it expected to declare an annual dividend representing 60% to 80% of its NPAT.

($1 = 1.3935 Australian dollars) (Reporting by Tejaswi Marthi in Bengaluru; Editing by Shounak Dasgupta and Ramakrishnan M.)


© Reuters 2021
All news about EBOS GROUP LIMITED
06/19EBOS : Application for quotation of securities - EBO
PU
05/30EBOS : Appendix 2A
PU
04/19EBOS : Application for quotation of securities - EBO
PU
03/30EBOS : Correction to ASX Appendix 2A
PU
03/24EBOS' proposed acquisition of Pacific Health Group not opposed
AQ
03/24Competition Watchdog Clears EBOS' Acquisition of Medical Device Firm
MT
03/21Ebos Group's TerryWhite Chemmart, Opens 500th Pharmacy
MT
03/20EBOS GROUP LIMITED(NZSE : EBO) added to FTSE All-World Index
CI
03/15EBOS : Application for quotation of securities - EBO
PU
02/22EBOS : Notification regarding unquoted securities - EBO
PU
More news
Financials
Sales 2022 11 349 M 7 017 M 7 017 M
Net income 2022 239 M 148 M 148 M
Net Debt 2022 1 010 M 624 M 624 M
P/E ratio 2022 26,6x
Yield 2022 2,65%
Capitalization 7 161 M 4 427 M 4 427 M
EV / Sales 2022 0,72x
EV / Sales 2023 0,66x
Nbr of Employees 3 105
Free-Float 84,9%
Chart EBOS GROUP LIMITED
Duration : Period :
EBOS Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EBOS GROUP LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 37,81 NZD
Average target price 40,61 NZD
Spread / Average Target 7,41%
EPS Revisions
Managers and Directors
John Cullity Chief Executive Officer
Leonard Hansen Chief Financial Officer
Elizabeth Mary Coutts Chairman
Andrea Bell Chief Information Officer
Sarah Christine Ottrey Independent Non-Executive Director
Sector and Competitors